QuidelOrtho Appoints Erich Wolff as Executive VP to Strengthen Leadership and Strategy

QuidelOrtho Elevates Strategic Leadership with New Executive Appointment

QuidelOrtho Corporation, a prominent player in the in vitro diagnostics industry, strengthens its leadership team with the appointment of Erich Wolff as Executive Vice President of Strategy & Corporate Development. Reporting directly to President and CEO Brian Blaser, Wolff assumes a pivotal role in shaping the company's enterprise strategy, business development, government affairs, and portfolio management. His extensive experience, spanning over two decades in the healthcare and diagnostics sectors, positions him as a strategic asset for QuidelOrtho as it seeks to enhance its operational effectiveness and market reach.

Wolff's background is marked by significant achievements in strategy and mergers and acquisitions, particularly during his tenure at Partners Group, where he led initiatives in MedTech and Life Sciences Tools & Diagnostics. His leadership experience at industry giants like BD and Medtronic equips him with the insights necessary to navigate the complex landscape of diagnostics. Notably, he played a critical role in revitalizing Medtronic's global diabetes business and orchestrating major corporate transformations, including the strategic spinoff of embecta from BD. These experiences underline his capability to drive substantial growth and innovation, aligning perfectly with QuidelOrtho's mission to advance the future of diagnostics.

As Wolff takes on this new role, he expresses enthusiasm for QuidelOrtho's commitment to innovation and its robust global presence. His vision focuses on collaborating closely with the leadership team to develop and implement strategies that will not only foster growth but also deliver long-term value to stakeholders. Brian Blaser commends Wolff’s strategic vision and operational expertise, emphasizing that his arrival comes at a crucial time as the company aims to strengthen its position in the diagnostics market.

In addition to Wolff's appointment, QuidelOrtho continues to focus on expanding its innovative product offerings. The company remains dedicated to advancing diagnostic solutions that address pressing healthcare challenges, ensuring that it stays at the forefront of technological advancements in the industry. This alignment of strategic leadership and innovative product development is expected to solidify QuidelOrtho's competitive advantage in the evolving diagnostics landscape.

As the company navigates its growth trajectory, Wolff's leadership is anticipated to play a significant role in shaping its future direction, further enhancing its capabilities in delivering impactful diagnostics solutions to healthcare providers and patients worldwide.